| review article | Q7318358 |
| scholarly article | Q13442814 |
| medical guideline | Q878041 |
| P2093 | author name string | Korean Society of Abdominal Radiology | |
| P2860 | cites work | Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region | Q26750444 |
| Noninvasive Diagnosis of Hepatocellular Carcinoma: Elaboration on Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guidelines Compared with Other Guidelines and Remaining Issues | Q26770020 | ||
| Recent Advances in Tumor Ablation for Hepatocellular Carcinoma | Q26775418 | ||
| JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan | Q26797521 | ||
| Management of hepatocellular carcinoma: An update | Q27860530 | ||
| EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma | Q27860783 | ||
| Recent Advances in the Imaging Diagnosis of Hepatocellular Carcinoma: Value of Gadoxetic Acid-Enhanced MRI | Q28075361 | ||
| Consensus report from the 7th International Forum for Liver Magnetic Resonance Imaging | Q28088807 | ||
| 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma | Q28394414 | ||
| Hepatocellular carcinoma | Q29615765 | ||
| LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. | Q30837374 | ||
| Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths | Q31011793 | ||
| Liver imaging reporting and data system v2014 categorization of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: Comparison with multiphasic multidetector computed tomography | Q31118557 | ||
| Hepatocellular carcinoma: correlation of MR imaging and histopathologic findings | Q67488414 | ||
| Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence | Q71084509 | ||
| Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging | Q72246149 | ||
| Focal liver lesions: pattern-based classification scheme for enhancement at arterial phase CT | Q73834861 | ||
| Rapidly enhancing hepatic hemangiomas at MRI: distinction from malignancies with T2-weighted images | Q73945349 | ||
| The role of dynamic subtraction MRI in detection of hepatocellular carcinoma | Q82859749 | ||
| Focal nodular hyperplasia or focal nodular hyperplasia-like lesions of the liver: a special emphasis on diagnosis | Q83247904 | ||
| Fate of hypointense lesions on Gd-EOB-DTPA-enhanced magnetic resonance imaging | Q83332632 | ||
| Vascular enhancement in early dynamic liver MR imaging in an animal model: comparison of two injection regimen and two different doses Gd-EOB-DTPA (gadoxetic acid) with standard Gd-DTPA | Q83885479 | ||
| Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triple-phase multidetector CT imaging | Q84153727 | ||
| Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: characterization with gadoxetic acid-enhanced MRI that includes diffusion-weighted imaging | Q84178634 | ||
| The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging | Q84230646 | ||
| Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow | Q84274443 | ||
| Can MR fluoroscopic triggering technique and slow rate injection provide appropriate arterial phase images with reducing artifacts on gadoxetic acid-DTPA (Gd-EOB-DTPA)-enhanced hepatic MR imaging? | Q84631273 | ||
| Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MRI: risk of HCC recurrence after radiofrequency ablation | Q86368066 | ||
| Subcentimeter hypervascular nodule with typical imaging findings of hepatocellular carcinoma in patients with history of hepatocellular carcinoma: natural course on serial gadoxetic acid-enhanced MRI and diffusion-weighted imaging | Q86860851 | ||
| Timing of the hepatic arterial phase at Gd-EOB-DTPA-enhanced hepatic dynamic MRI: comparison of the test-injection and the fixed-time delay method | Q86912977 | ||
| Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout? | Q86935141 | ||
| Is liver-specific gadoxetic acid-enhanced magnetic resonance imaging a reliable tool for detection of hepatocellular carcinoma in patients with chronic liver disease? | Q87145592 | ||
| Risk of hypervascularization in small hypovascular hepatic nodules showing hypointense in the hepatobiliary phase of gadoxetic acid-enhanced MRI in patients with chronic liver disease | Q87354364 | ||
| Imaging features of subcentimeter hypointense nodules on gadoxetic acid-enhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease | Q87899087 | ||
| Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan | Q34091171 | ||
| Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? | Q34584992 | ||
| Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. | Q34585928 | ||
| The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis | Q34614340 | ||
| Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma | Q34626532 | ||
| CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects | Q34681076 | ||
| CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features | Q34682228 | ||
| Early hepatocellular carcinoma as an entity with a high rate of surgical cure | Q34754443 | ||
| Small hepatocellular carcinoma: relationship of signal intensity to histopathologic findings and metal content of the tumor and surrounding hepatic parenchyma | Q34756326 | ||
| Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis | Q35537922 | ||
| Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver | Q36024724 | ||
| Updated treatment approach to hepatocellular carcinoma. | Q36097844 | ||
| Hepatocellular carcinoma in cirrhosis: enhancement patterns at dynamic gadolinium- and superparamagnetic iron oxide-enhanced T1-weighted MR imaging | Q36271427 | ||
| Importance of small (< or = 20-mm) enhancing lesions seen only during the hepatic arterial phase at MR imaging of the cirrhotic liver: evaluation and comparison with whole explanted liver. | Q36321419 | ||
| Liver transplantation for hepatocellular carcinoma in Asia | Q37022894 | ||
| Microvascular invasion does not predict long-term survival in hepatocellular carcinoma up to 2 cm: reappraisal of the staging system for solitary tumors | Q37375773 | ||
| The MR imaging diagnosis of liver diseases using gadoxetic acid: emphasis on hepatobiliary phase | Q37488806 | ||
| Liver Transplantation: East versus West | Q37613378 | ||
| Anatomic pathology of hepatocellular carcinoma: impact on prognosis and response to therapy | Q37892063 | ||
| Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease | Q37948739 | ||
| Value of subtraction MRI in assessing treatment response following image-guided loco-regional therapies for hepatocellular carcinoma | Q37980954 | ||
| Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images. | Q38026533 | ||
| Small hepatocellular carcinomas: improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns | Q38030499 | ||
| Hypovascular hypointense nodules on hepatobiliary phase gadoxetic acid-enhanced MR images in patients with cirrhosis: potential of DW imaging in predicting progression to hypervascular HCC. | Q38034517 | ||
| Added value of subtraction imaging in detecting arterial enhancement in small (<3 cm) hepatic nodules on dynamic contrast-enhanced MRI in patients at high risk of hepatocellular carcinoma. | Q38058687 | ||
| Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality | Q38063463 | ||
| Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma | Q38077746 | ||
| Newly developed hypervascular hepatocellular carcinoma during follow-up periods in patients with chronic liver disease: observation in serial gadoxetic acid-enhanced MRI. | Q38108800 | ||
| Liver lesion detection and characterization: role of diffusion-weighted imaging. | Q38109869 | ||
| Respiratory motion artifact affecting hepatic arterial phase imaging with gadoxetate disodium: examination recovery with a multiple arterial phase acquisition | Q38183097 | ||
| Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis | Q56985572 | ||
| Gadoxetate Disodium-Enhanced MRI to Differentiate Dysplastic Nodules and Grade of Hepatocellular Carcinoma: Correlation With Histopathology | Q57158900 | ||
| Dynamic enhancement pattern of HCC smaller than 3 cm in diameter on gadoxetic acid-enhanced MRI: comparison with multiphasic MDCT | Q59115810 | ||
| Optimization of imaging diagnosis of 1–2cm hepatocellular carcinoma: An analysis of diagnostic performance and resource utilization | Q61736906 | ||
| The Clinical Outcome of Small (<20 mm) Arterially Enhancing Nodules on MRI in the Cirrhotic Liver | Q63432587 | ||
| Small (≤1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging | Q38192716 | ||
| Matched within-patient cohort study of transient arterial phase respiratory motion-related artifact in MR imaging of the liver: gadoxetate disodium versus gadobenate dimeglumine | Q38195093 | ||
| Multimodal treatment of hepatocellular carcinoma | Q38199214 | ||
| Hepatobiliary MR contrast agents in hypovascular hepatocellular carcinoma | Q38238010 | ||
| Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings | Q38247341 | ||
| Preoperative gadoxetic Acid-enhanced MRI and simultaneous treatment of early hepatocellular carcinoma prolonged recurrence-free survival of progressed hepatocellular carcinoma patients after hepatic resection. | Q38255718 | ||
| Hepatobiliary agents and their role in LI-RADS. | Q38257321 | ||
| Non-hypervascular hypointense nodules ≥1 cm on the hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging in cirrhotic livers | Q38265712 | ||
| Surveillance and diagnostic algorithm for hepatocellular carcinoma proposed by the Liver Cancer Study Group of Japan: 2014 update | Q38271758 | ||
| Nonhypervascular Hypointense Nodules at Gadoxetic Acid-enhanced MR Imaging in Chronic Liver Disease: Diffusion-weighted Imaging for Characterization | Q38367157 | ||
| The Impact of Tumor Size on Long-Term Survival Outcomes After Resection of Solitary Hepatocellular Carcinoma: Single-Institution Experience with 2558 Patients | Q38426156 | ||
| Cirrhotic liver: What's that nodule? The LI-RADS approach. | Q38495409 | ||
| Diagnosing Borderline Hepatic Nodules in Hepatocarcinogenesis: Imaging Performance. | Q38535294 | ||
| Added value of smooth hypointense rim in the hepatobiliary phase of gadoxetic acid-enhanced MRI in identifying tumour capsule and diagnosing hepatocellular carcinoma. | Q39259950 | ||
| Outcomes of follow-up CT for small (5-10-mm) arterially enhancing nodules in the liver and risk factors for developing hepatocellular carcinoma in a surveillance population | Q39862490 | ||
| Intrahepatic Cholangiocarcinoma in the Liver Explant After Liver Transplantation: Histological Differentiation and Prognosis | Q40805986 | ||
| The Diagnostic Performance of Dynamic Contrast-enhanced MR Imaging for Detection of Small Hepatocellular Carcinoma Measuring Up to 2 cm: A Meta-Analysis. | Q40812280 | ||
| "Pseudo washout" sign in high-flow hepatic hemangioma on gadoxetic acid contrast-enhanced MRI mimicking hypervascular tumor | Q43236786 | ||
| Marginal survival benefit in the treatment of early hepatocellular carcinoma | Q43700512 | ||
| Hypovascular hypointense nodules on hepatocyte phase gadoxetic acid-enhanced MR images: too early or too progressed to determine hypervascularity | Q44468769 | ||
| Optimal scanning protocol of arterial dominant phase for hypervascular hepatocellular carcinoma with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced MR. | Q44836994 | ||
| Hypovascular hepatic nodule showing hypointensity in the hepatobiliary phase of gadoxetic acid-enhanced MRI in patients with chronic liver disease: prediction of malignant transformation. | Q46010523 | ||
| Imaging features of intrahepatic cholangiocarcinoma in Gd-EOB-DTPA-enhanced MRI. | Q46435374 | ||
| Small hypervascular enhancing lesions on arterial phase images of multiphase dynamic computed tomography in cirrhotic liver: fate and implications. | Q46731307 | ||
| Transient respiratory motion artifact during arterial phase MRI with gadoxetate disodium: risk factor analyses | Q47568370 | ||
| Comparison of MRI with liver-specific contrast agents and multidetector row CT for the detection of hepatocellular carcinoma: a meta-analysis of 15 direct comparative studies. | Q47821895 | ||
| No Need of Immediate Treatment for Hypovascular Tumors Associated with Hepatocellular Carcinoma | Q50241691 | ||
| Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. | Q51000636 | ||
| Presence of a hypovascular hepatic nodule showing hypointensity on hepatocyte-phase image is a risk factor for hypervascular hepatocellular carcinoma. | Q51028212 | ||
| Which is the best MRI marker of malignancy for atypical cirrhotic nodules: hypointensity in hepatobiliary phase alone or combined with other features? Classification after Gd-EOB-DTPA administration. | Q51367260 | ||
| The radiological diagnosis of hepatocellular carcinoma. | Q51716565 | ||
| High-flow haemangiomas versus hypervascular hepatocellular carcinoma showing "pseudo-washout" on gadoxetic acid-enhanced hepatic MRI: value of diffusion-weighted imaging in the differential diagnosis of small lesions. | Q52965065 | ||
| Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver. | Q53071283 | ||
| Radial volumetric imaging breath-hold examination (VIBE) with k-space weighted image contrast (KWIC) for dynamic gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI of the liver: advantages over Cartesian VIBE in the arterial phase. | Q53074951 | ||
| Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis. | Q53109359 | ||
| Planning ultrasound for percutaneous radiofrequency ablation to treat small (≤ 3 cm) hepatocellular carcinomas detected on computed tomography or magnetic resonance imaging: a multicenter prospective study to assess factors affecting ultrasound visi | Q53172650 | ||
| Diagnostic criteria for hepatocellular carcinoma ⩽3 cm with hepatocyte-specific contrast-enhanced magnetic resonance imaging. | Q53192468 | ||
| Comparison of three different injection methods for arterial phase of Gd-EOB-DTPA enhanced MR imaging of the liver. | Q53246208 | ||
| Targeted sonography for small hepatocellular carcinoma discovered by CT or MRI: factors affecting sonographic detection. | Q53299046 | ||
| Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. | Q53508322 | ||
| Non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of outcomes for early-stage HCC. | Q53577913 | ||
| Comparison of diffusion-weighted imaging and gadoxetic acid-enhanced MR images in the evaluation of hepatocellular carcinoma and hypovascular hepatocellular nodules. | Q53591709 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | gadopentetate dimeglumine | Q413793 |
| hepatocellular carcinoma | Q1148337 | ||
| contrast agent | Q6849688 | ||
| liver neoplasm | Q18558073 | ||
| P1104 | number of pages | 17 | |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 427-443 | |
| P577 | publication date | 2017-04-03 | |
| P1433 | published in | Korean journal of radiology : official journal of the Korean Radiological Society | Q26842124 |
| P1476 | title | Diagnosis of Hepatocellular Carcinoma with Gadoxetic Acid-Enhanced MRI: 2016 Consensus Recommendations of the Korean Society of Abdominal Radiology | |
| P478 | volume | 18 |
| Q92108212 | A Glimpse on Trends and Characteristics of Recent Articles Published in the Korean Journal of Radiology |
| Q90045156 | Contrast-enhanced ultrasound of hepatocellular carcinoma: where do we stand? |
| Q47326179 | Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI. |
| Q92319410 | Emerging Role of Hepatobiliary Magnetic Resonance Contrast Media and Contrast-Enhanced Ultrasound for Noninvasive Diagnosis of Hepatocellular Carcinoma: Emphasis on Recent Updates in Major Guidelines |
| Q64117986 | Identification of Arterial Hyperenhancement in CT and MRI in Patients with Hepatocellular Carcinoma: Value of Unenhanced Images |
| Q92108249 | Intraindividual Comparison between Gadoxetate-Enhanced Magnetic Resonance Imaging and Dynamic Computed Tomography for Characterizing Focal Hepatic Lesions: A Multicenter, Multireader Study |
| Q55384238 | Noninvasive imaging of hepatocellular carcinoma: From diagnosis to prognosis. |
| Q89425004 | Optimal criteria for hepatocellular carcinoma diagnosis using CT in patients undergoing liver transplantation |
| Q90480934 | Relationship between platelet-based models and the prognosis of patients with malignant hepatic tumors |
| Q90528423 | Second shot arterial phase to overcome degraded hepatic arterial phase in liver MR imaging |
| Q55424498 | The Diagnostic Performance of Liver MRI without Intravenous Contrast for Detecting Hepatocellular Carcinoma: A Case-Controlled Feasibility Study. |
| Q91594116 | The Optimal Management for Sub-Centimeter Hepatocellular Carcinoma: Curative Treatments or Follow-Up? |
Search more.